摘要
Mycoplasma bovis is an important pathogen causing mostly pneumonia in calves and mastitis in dairy cattle. In the absence of an effective vaccine, antimicrobial therapy remains the main control measure. Antimicrobial use in veal calves is substantially higher than in conventional herds, but whether veal calves also harbor more resistant M. bovis strains is currently unknown. Therefore, we compared antimicrobial susceptibility test results of M. bovis isolates from different cattle sectors and genomic clusters. The minimum inhibitory concentration of nine antimicrobials was determined for 141 Belgian M. bovis isolates (29 dairy, 69 beef, 12 mixed, 31 veal farms), and was used to estimate the epidemiological cut-off. Acquired resistance was frequently observed for the macrolides, while no acquired resistance to oxytetracycline and doxycycline, minimal acquired resistance to florfenicol and tiamulin, and a limited acquired resistance to enrofloxacin was seen. M. bovis isolates from beef cattle or genomic cluster III had higher odds of being gamithromycin-resistant than those from dairy cattle or genomic clusters IV and V. In this study, no cattle industry could be identified as source of resistant M. bovis strains. A single guideline for antimicrobial use for M. bovis infections, with a small remark for gamithromycin, is likely sufficient.
摘要译文
支原体Bovis是一种重要的病原体,导致奶牛和乳制品中的牛犊和乳腺炎的肺炎。在没有有效疫苗的情况下,抗微生物治疗仍然是主要的控制措施。在小牛犊中使用的抗菌剂基本上高于传统畜群,但是小牛犊是否含有更抗性的M. Bovis菌株目前未知。因此,我们比较了来自不同牛行业和基因组簇的M. Bovis分离株的抗微生物易感性测试结果。测定九种抗微生物的最小抑制浓度为141个Belgian M. Bovis分离株(29个乳制品,69只牛肉,12名混合,31个小牛肉场),并用于估算流行病学截止。对于大溴化物经常观察到获得的抗性,同时没有获得对氧赤氧化碳和强霉素的耐受性,最小的获得氟苯硅酸和脂蛋素的抗性,以及对苯甲烷的有限的获得性抗性。 M. Bovis来自牛肉或基因组簇III的分离物的抗性耐菌霉素的几率高于来自乳制品牛或基因组簇IV和V的抗性。在本研究中,没有牛行业可以被鉴定为抗性M. Bovis菌株的来源。对博古斯感染的抗菌剂使用的单一指南,对于Gamithromycin具有小写,可能是足够的。
Jade Bokma[ 1;2;[*]; Linde Gille[ 1;†]; Koen De Bleecker[ 3]; Jozefien Callens[ 3]; Freddy Haesebrouck[ 2]; Bart Pardon[ 1;‡];Filip Boyen[ 2;‡]. Antimicrobial Susceptibility of Mycoplasma bovis Isolates from Veal, Dairy and Beef Herds[J]. Antibiotics, 2020,9(12): 882